Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Intangibles (2017 - 2025)

Adma Biologics (ADMA) has disclosed Intangibles for 9 consecutive years, with $632000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles rose 37.39% year-over-year to $632000.0, compared with a TTM value of $632000.0 through Dec 2025, up 37.39%, and an annual FY2025 reading of $632000.0, up 37.39% over the prior year.
  • Intangibles was $632000.0 for Q4 2025 at Adma Biologics, up from $491000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $6.1 million in Q3 2021 and bottomed at $452000.0 in Q1 2025.
  • Average Intangibles over 5 years is $2.3 million, with a median of $655740.0 recorded in 2023.
  • The sharpest move saw Intangibles soared 1067.12% in 2024, then plummeted 91.36% in 2025.
  • Year by year, Intangibles stood at $1.7 million in 2021, then skyrocketed by 189.63% to $5.0 million in 2022, then crashed by 90.03% to $499000.0 in 2023, then decreased by 7.82% to $460000.0 in 2024, then soared by 37.39% to $632000.0 in 2025.
  • Business Quant data shows Intangibles for ADMA at $632000.0 in Q4 2025, $491000.0 in Q3 2025, and $527000.0 in Q2 2025.